不可切除局部晚期胰腺癌放疗剂量递增联合或不联合诱导化疗
基于美国国家癌症数据库(NCDB)分析2029例III期cT4 N0-1 M0局部晚期胰腺癌患者,比较常规分割放疗(CFRT)剂量<55 Gy与≥55 Gy在联合或不联合诱导化疗(iC)时的总生存差异,发现仅iC+放化疗组剂量递增与生存改善相关,无iC组未见明确关联。
要点
- iC+放化疗组剂量≥55 Gy较45-55 Gy改善总生存(HR 0.77,p=0.013)。
- 倾向评分匹配后iC+放化疗组剂量递增仍显著(中位OS 16.2 vs 15.2个月,p=0.022)。
- 无iC的放化疗组剂量递增与生存无显著关联(匹配后p=0.16)。
核心结论
- 接受诱导化疗的局部晚期胰腺癌患者,放疗剂量递增至55 Gy以上与生存改善相关。
- 未接受诱导化疗的患者,放疗剂量递增与生存之间未见明确关联。
研究设计与样本
- 查询美国国家癌症数据库(NCDB)2004-2015年原发III期、cT4 N0-1 M0局部晚期胰腺癌接受放化疗(伴或不伴诱导化疗)的患者。
- 常规分割放疗按<55 Gy和≥55 Gy分层,iC+放化疗队列738例(45-55 Gy 601例,≥55 Gy 137例),放化疗队列1291例(45-55 Gy 1066例,≥55 Gy 225例)。
- 主要终点为总生存,采用Kaplan-Meier分析、Cox比例风险模型和倾向评分匹配。
主要发现
- iC+放化疗队列中位随访24.3个月,放化疗队列中位随访24.6个月。
- 多因素分析中,剂量递增在iC+放化疗队列与生存改善相关(HR 0.77,p=0.013),在放化疗队列不显著(HR 0.91,p=0.19)。
- 2:1倾向评分匹配后,iC+放化疗队列匹配387例,放化疗队列匹配549例。
- 匹配后iC+放化疗队列剂量递增仍显著改善总生存(中位OS 16.2 vs 15.2个月;2年OS 33.4% vs 25.4%;p=0.022)。
- 匹配后放化疗队列剂量递增与总生存无显著关联(中位OS 11.8 vs 10.6个月;2年OS 13.3% vs 10.1%;p=0.16)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dose escalation of conventionally fractionated radiation therapy (CFRT) above 45-54 Gy has an unclear survival benefit. Prior National Cancer Database (NCDB) analyses have shown improved overall survival with induction chemotherapy (iC) prior to concurrent chemoradiation (CRT) in locally advanced pancreatic cancer. Our study compared dose-escalated CFRT with and without iC. METHODS: The NCDB was queried for primary stage III, cT4 N0-1 M0 LAPC treated with CRT with or without iC (2004-2015). CFRT was stratified by < 55 Gy and ≥ 55 Gy. Cohort iC + CRT and CRT included those with and without iC, respectively. The primary endpoint was overall survival (OS). Kaplan-Meier analysis, Cox proportional hazards method, and propensity score matching were used. RESULTS: Among 2029 patients, cohort iC + CRT had 738 patients (n = 601 for 45-55 Gy and n = 137 for ≥55 Gy) and cohort CRT had 1291 patients (n = 1066 for 45-55 Gy and n = 225 for ≥55 Gy). Median follow-up was 24.3 months and 24.6 months for cohorts iC + CRT and CRT, respectively. Dose escalation showed improved survival in the multivariable analysis in cohort iC + CRT (HR 0.77, p = 0.013) but not in cohort CRT (HR 0.91, p = 0.19). Using 2:1 propensity score matching, a total of 387 patients for cohort iC + CRT and 549 patients for cohort CRT were matched. After matching, dose escalation remained significant for improved overall survival in cohort iC + CRT (median OS 16.2 vs 15.2 months; 2-yr OS 33.4% vs 25.4%; p = 0.022) but not in cohort CRT (median OS 11.8 vs 10.6 months; 2-yr OS 13.3% vs 10.1%; p = 0.16). CONCLUSIONS: Patients with locally advanced pancreatic cancer who undergo iC have improved survival with radiation dose escalation above 55 Gy. For patients without iC, there is no clear association between radiation dose escalation and survival.
引用
- Ma SJ, Prezzano KM, Hermann GM, et al. Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer. Radiat Oncol. 2018. PMID: 30400962. doi:10.1186/s13014-018-1158-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。